Related Experiment Video
Updated: Oct 12, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual
Sushmitha Sankarasubramanian1,2, Ulrike Pfohl1,3,4, Christian R A Regenbrecht1,3,5
1CELLphenomics GmbH, Berlin, Germany.
Abstract:
Pancreatic cancer is one of the deadliest cancers and remains a major unsolved health problem. While pancreatic ductal adenocarcinoma (PDAC) is associated with driver mutations in only four major genes (KRAS, TP53, SMAD4, and CDKN2A), every tumor differs in its molecular landscape, histology, and prognosis. It is crucial to understand and consider these differences to be able to tailor treatment regimens specific to the vulnerabilities of the individual tumor to enhance patient outcome. This review focuses on the heterogeneity of pancreatic tumor cells and how in addition to genetic alterations, the subsequent dysregulation of multiple signaling cascades at various levels, epigenetic and metabolic factors contribute to the oncogenesis of PDAC and compensate for each other in driving cancer progression if one is tackled by a therapeutic approach. This implicates that besides the need for new combinatorial therapies for PDAC, a personalized approach for treating this highly complex cancer is required. A strategy that combines both a target-based and phenotypic approach to identify an effective treatment, like Reverse Clinical Engineering® using patient-derived organoids, is discussed as a promising way forward in the field of personalized medicine to tackle this deadly disease.
Insights
Pancreatic cancer (PDAC) is complex due to tumor heterogeneity. Personalized treatments, like Reverse Clinical Engineering with organoids, are vital for improving outcomes against this deadly disease.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), is a leading cause of cancer death with limited treatment options.
- Despite known driver mutations (KRAS, TP53, SMAD4, CDKN2A), PDAC exhibits significant molecular and histological heterogeneity, impacting prognosis.
- Understanding individual tumor characteristics is essential for developing effective, tailored treatment strategies.
Purpose of the Study:
- To review the heterogeneity of pancreatic tumor cells and contributing factors to PDAC oncogenesis.
- To highlight the need for personalized and combinatorial therapeutic approaches.
- To discuss Reverse Clinical Engineering using patient-derived organoids as a promising strategy for personalized PDAC treatment.
Main Methods:
- Review of current literature on pancreatic cancer heterogeneity, molecular landscapes, and signaling pathways.
- Analysis of genetic alterations, epigenetic factors, and metabolic dysregulation in PDAC.
- Discussion of Reverse Clinical Engineering (RCE) combined with patient-derived organoids (PDOs) for treatment strategy development.
Main Results:
- PDAC oncogenesis is driven by genetic mutations, signaling cascade dysregulation, and epigenetic/metabolic factors.
- Tumor heterogeneity allows cancer cells to compensate for therapeutic interventions, necessitating multifaceted treatment strategies.
- Patient-derived organoids offer a platform for evaluating drug efficacy and tailoring treatments.
Conclusions:
- A personalized approach is crucial for treating the complex and heterogeneous nature of PDAC.
- Combining target-based and phenotypic strategies, such as RCE with PDOs, shows promise for advancing personalized medicine in pancreatic cancer.
- Addressing PDAC's complexity requires innovative therapeutic strategies beyond single-target approaches.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:18Cancer
02:56Treatment Resistant Cancers
01:24Dosage Regimen: Individualization